Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Nov 1, 2022
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2022-10-28−10,000→ 86,995 totalExercise: $1.48Exp: 2029-09-16→ Common Stock (10,000 underlying) - Sale
Common Stock
2022-10-28$39.90/sh−10,000$399,000→ 6,629 total - Exercise/Conversion
Common Stock
2022-10-28$1.48/sh+10,000$14,800→ 16,629 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
- [F2]The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.